Skip Navigation Links.
Collapse <span class="m110 colortj mt20 fontw700">Volume 12 (2024)</span>Volume 12 (2024)
Collapse <span class="m110 colortj mt20 fontw700">Volume 11 (2023)</span>Volume 11 (2023)
Collapse <span class="m110 colortj mt20 fontw700">Volume 10 (2022)</span>Volume 10 (2022)
Collapse <span class="m110 colortj mt20 fontw700">Volume 9 (2021)</span>Volume 9 (2021)
Collapse <span class="m110 colortj mt20 fontw700">Volume 8 (2020)</span>Volume 8 (2020)
Collapse <span class="m110 colortj mt20 fontw700">Volume 7 (2019)</span>Volume 7 (2019)
Collapse <span class="m110 colortj mt20 fontw700">Volume 6 (2018)</span>Volume 6 (2018)
Collapse <span class="m110 colortj mt20 fontw700">Volume 5 (2017)</span>Volume 5 (2017)
Collapse <span class="m110 colortj mt20 fontw700">Volume 4 (2016)</span>Volume 4 (2016)
Collapse <span class="m110 colortj mt20 fontw700">Volume 3 (2015)</span>Volume 3 (2015)
Collapse <span class="m110 colortj mt20 fontw700">Volume 2 (2014)</span>Volume 2 (2014)
Collapse <span class="m110 colortj mt20 fontw700">Volume 1 (2013)</span>Volume 1 (2013)
American Journal of Medical Case Reports. 2021, 9(6), 339-341
DOI: 10.12691/AJMCR-9-6-9
Case Report

Multiple Sclerosis Spastic Pain Relief Secondary to Medicinal Marijuana

Eric J. Basile1, 2, , Aaron Campeas1, Omar Rafa1 and Autumn Breutzmann1

1Touro College of Osteopathic Medicine, NY, New York, United States

2Holy Name Medical Center, Teaneck, NJ, United States

Pub. Date: March 30, 2021
Full Text PDF

Cite this paper

Eric J. Basile, Aaron Campeas, Omar Rafa and Autumn Breutzmann. Multiple Sclerosis Spastic Pain Relief Secondary to Medicinal Marijuana. American Journal of Medical Case Reports. 2021; 9(6):339-341. doi: 10.12691/AJMCR-9-6-9

Abstract

A 57-year-old male presented to an outpatient Multiple Sclerosis (MS) clinic for excruciating spastic pain secondary to MS. After a trial of multiple pain management drugs with no success, he began a trial of marijuana. In this paper, we report the extent of improvement in quality of life secondary to cannabinoid use after failing multimodal pain management regimens.

Keywords

multiple sclerosis, pain management, medicinal marijuana, cannabinoids

Copyright

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]  Wallin, Mitchell T., et al. “The Prevalence of MS in the United States.” Neurology, vol. 92, no. 10, 2019,
 
[2]  Hill, Kevin P. “Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems.” Jama, vol. 313, no. 24, 2015, p. 2474.
 
[3]  “Stem Cell Therapy and MS.” Bioeden US, The Multiple Sclerosis Foundation, 17 May 2018, www.bioeden.com/us/treatment/stem-cell-therapy-ms/.
 
[4]  Truini, A, et al. “A Mechanism-Based Classification of Pain in Multiple Sclerosis.” Journal of Neurology, Springer-Verlag, Feb. 2013, www.ncbi.nlm.nih.gov/pmc/articles/PMC3566383/.
 
[5]  Hugos CL, Cameron MH. Assessment and Measurement of Spasticity in MS: State of the Evidence. Curr Neurol Neurosci Rep. 2019 Aug 30; 19(10): 79.
 
[6]  Vijayasingham L, Mairami FF. Employment of patients with multiple sclerosis: the influence of psychosocial-structural coping and context. Degener Neurol Neuromuscul Dis. 2018 Mar 26; 8: 15-24.
 
[7]  Coyne KS, Boscoe AN, Currie BM, Landrian AS, Wandstrat TL. Understanding Drivers of Employment Changes in a Multiple Sclerosis Population. Int J MS Care. 2015 Sep-Oct; 17(5): 245-52.
 
[8]  Schabas, A., Vukojevic, V., Taylor, C., Thu, Z., Badyal, A., Chan, J., Carruthers, R. (2019). Cannabis-based product use in a multiple sclerosis cohort. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 5(3), 205521731986936.
 
[9]  Rice, Jessica, and Michelle Cameron. “Cannabinoids for Treatment of MS Symptoms: State of the Evidence.” Current Neurology and Neuroscience Reports, U.S. National Library of Medicine, 19 June 2018, www.ncbi.nlm.nih.gov/pubmed/29923025.